Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $35.71.

Several research firms have recently weighed in on DAWN. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $11.00 to $24.00 in a research note on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th.

Insider Buying and Selling

In other news, General Counsel Adam Dubow sold 3,202 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares of the company’s stock, valued at $376,992. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Jeremy Bender sold 10,681 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $149,534.00. Following the completion of the sale, the chief executive officer now owns 98,932 shares in the company, valued at approximately $1,385,048. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $44,828.00. Following the completion of the sale, the general counsel now directly owns 26,928 shares in the company, valued at approximately $376,992. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,748 shares of company stock worth $714,572. 8.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its position in shares of Day One Biopharmaceuticals by 8.2% during the fourth quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock worth $195,000 after acquiring an additional 1,010 shares in the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $254,000. New York State Common Retirement Fund lifted its holdings in Day One Biopharmaceuticals by 20.5% during the 4th quarter. New York State Common Retirement Fund now owns 78,299 shares of the company’s stock worth $1,143,000 after purchasing an additional 13,294 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Day One Biopharmaceuticals by 88.9% in the 4th quarter. Fisher Asset Management LLC now owns 68,411 shares of the company’s stock worth $999,000 after purchasing an additional 32,203 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Day One Biopharmaceuticals by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 452,934 shares of the company’s stock valued at $6,613,000 after buying an additional 5,796 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN opened at $14.09 on Tuesday. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $18.07. The company has a market capitalization of $1.23 billion, a PE ratio of -5.61 and a beta of -1.51. The company has a fifty day moving average of $14.07 and a 200-day moving average of $14.79.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million. On average, equities analysts forecast that Day One Biopharmaceuticals will post -2.29 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.